Astellas Pharma

Astellas Pharma EBIT per Share

The EBIT per Share of Astellas Pharma (4503.T) as of Nov 2, 2026 is 233.66 JPY. In the previous year, EBIT per Share was 146.62 JPY — a change of 59.36% (higher).

EBIT per Share

233.66JPY

YoY

59.36%

Last updated:

EBIT per Share of Astellas Pharma is 2026 233.66 JPY. EBIT per Share of Astellas Pharma was 2025 146.62 JPY. It decreases by 59.36% higher compared to the previous year.

The Astellas Pharma EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2024
69.62 JPY
Jan 1, 2025
146.62 JPY
Jan 1, 2026
233.66 JPY
Jan 1, 2027 (e)
251.50 JPY
Jan 1, 2028 (e)
236.13 JPY
Jan 1, 2029 (e)
178.64 JPY
Jan 1, 2030 (e)
210.46 JPY
Jan 1, 2031 (e)
184.53 JPY
The Astellas Pharma EBIT per Share history
YEAREBIT per ShareYoY
est184.53JPY-12.32%
est210.46JPY+17.81%
est178.64JPY-24.35%
est236.13JPY-6.11%
est251.50JPY+7.64%
233.66JPY+59.36%
146.62JPY+110.60%
69.62JPY-56.09%
158.55JPY+31.41%
120.66JPY-10.85%
135.34JPY-9.98%
150.34JPY+0.69%
149.32JPY+5.89%
141.01JPY+2.97%
136.94JPY+7.56%
127.32JPY+26.68%
100.51JPY+20.27%
83.57JPY+22.53%
68.20JPY+19.77%
56.94JPY+10.33%
51.61JPY-36.06%
80.73JPY-25.55%
108.44JPY-9.25%
119.49JPY+12.65%
106.06JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Astellas Pharma Stock analysis

What does Astellas Pharma do? Astellas Pharma Inc. is a global pharmaceutical company based in Tokyo, Japan. The company manufactures and distributes medications worldwide. It was formed in April 2005 through the merger of two well-known Japanese pharmaceutical companies - Yamanouchi and Fujisawa. This merger created one of Japan's largest pharmaceutical companies and allowed for collaboration on the global market and the development of new innovations in medication research. Astellas' business model is focused on targeted research and development, comprehensive marketing and distribution networks, and collaboration with international partners. The company's main areas of focus are cancer, urology, transplantation, anti-infectives, and pneumology. Astellas has expanded its business through acquisitions and partnerships and currently operates in over 50 countries worldwide. In addition to pharmaceutical production, the company also provides services and consulting in the medical and health sectors. Astellas' business is divided into segments including pharmaceuticals, medical devices, and diagnostics. The pharmaceutical segment is the largest and offers a wide range of prescription medications for various medical areas. The medical devices segment specializes in the development and manufacturing of medical devices such as catheters, stents, and heart valves. The diagnostics segment focuses on developing and producing testing systems and instruments for diseases such as HIV and infectious diseases. Overall, Astellas is an important player in the global pharmaceutical and health industry, known for its innovative research, wide range of products, and collaboration with partners to develop campaigns against various diseases. Astellas Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Astellas Pharma stock

EBIT per Share of Astellas Pharma is 233.66 JPY in 2026.

EBIT per Share of Astellas Pharma changed from 146.62 JPY to 233.66 JPY, representing a 59.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Astellas Pharma since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Astellas Pharma

All Key Metrics — Astellas Pharma